SCHEMBL13113802

SCHEMBL13113802

CC(N)C(Cc1ccc(Cl)cc1)c1ccncc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.53
SLC6A3 Q01959 2/20 0.53
SLC6A4 P31645 2/20 0.47
CYP19A1 P11511 1/20 0.46
CNR1 P21554 4/20 0.45
CNR2 P34972 3/20 0.45
AKT1 P31749 2/20 0.40
ADRB2 P07550 1/20 0.40
CYP51A1 Q16850 1/20 0.39
ROCK2 O75116 1/20 0.39
PRKACA P17612 1/20 0.39
RPS6KB1 P23443 1/20 0.39
IRAK1 P51617 1/20 0.39
PRKX P51817 1/20 0.39
LIMK1 P53667 1/20 0.39
PRKG2 Q13237 1/20 0.39
ROCK1 Q13464 1/20 0.39
PRKG1 Q13976 1/20 0.39
PKN2 Q16513 1/20 0.39
HIPK4 Q8NE63 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3374963 0.98 SLC6A2 (0.51) SLC6A2SLC6A3SLC6A4CYP19A1CNR1
SCHEMBL8622261 0.94 SLC6A2 (0.49) SLC6A2SLC6A3SLC6A4CYP19A1CNR1
SCHEMBL4691720 0.88 SLC6A3 (0.62) SLC6A2SLC6A3SLC6A4CNR1CNR2
Hydrochloric Acid SCHEMBL3371509 0.86 SLC6A2 (0.60) SLC6A2SLC6A3SLC6A4CNR1CNR2
SCHEMBL27614823 0.83 SLC6A2 (0.56) SLC6A2SLC6A3SLC6A4CNR1CNR2
SCHEMBL3374924 0.83 SLC6A2 (0.56) SLC6A2SLC6A3SLC6A4CNR1CNR2
SCHEMBL3374922 0.83 SLC6A2 (0.56) SLC6A2SLC6A3SLC6A4CNR1CNR2
SCHEMBL8619441 0.83 SLC6A2 (0.56) SLC6A2SLC6A3SLC6A4CNR1CNR2
SCHEMBL8621289 0.83 SLC6A2 (0.56) SLC6A2SLC6A3SLC6A4CNR1CNR2
SCHEMBL3374829 0.83 SLC6A2 (0.51) SLC6A2SLC6A3SLC6A4CYP19A1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816534-B2 Substituted amides MERCK SHARP & DOHME CORP. (US) 2010-10-19 US disclosed
US-7816534-B2 Substituted amides MERCK SHARP & DOHME CORP. (US) 2010-10-19 US disclosed
US-7667053-B2 Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders MERCK & CO., INC. (US) 2010-02-23 US disclosed
US-7667053-B2 Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders MERCK & CO., INC. (US) 2010-02-23 US disclosed
US-20090258884-A1 Substituted amides MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-20090258884-A1 Substituted amides MERCK SHARP & DOHME CORP. 2009-10-15 US disclosed
US-7550489-B2 Substituted pyridyoxy amides MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-7550489-B2 Substituted pyridyoxy amides MERCK & CO., INC. (US) 2009-06-23 US disclosed
US-7423067-B2 N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse MERCK & CO., INC. (US) 2008-09-09 US disclosed
US-7423067-B2 N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse MERCK & CO., INC. (US) 2008-09-09 US disclosed
US-20080171692-A1 Substituted amides MERCK SHARP & DOHME CORP. 2008-07-17 US disclosed
US-20080171692-A1 Substituted amides MERCK SHARP & DOHME CORP. 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171692-A1 Substituted amides CNR1, CNR2, FAAH SLC6A2 1525/4885SLC6A3 2303/4885SLC6A4 2167/4885
US-20090258884-A1 Substituted amides CNR1, CNR2, FAAH SLC6A2 1525/4885SLC6A3 2303/4885SLC6A4 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.